News

Transgene Completes Initial Patient Screening In Phase II Part Of TG4050 Trial In Operable Head And Neck Cancer
Phase I part showed 100% Disease-Free Survival (DFS) after a minimum of 2-year follow-up – providing clinical proof of principle for TG4050 <p ...